Ze’ev Drukker

Ze’ev is a senior double majoring in biomedical engineering and biology, on track to graduate magna cum laude.

This past year, he took a gap year during which he pursued both professional and personal goals, including a co-op on the Product Management and Operations team at Cytiva.

Ze’ev is the CEO and Cofounder of JEZA Genomics, an early-stage startup out of Tufts attempting to use gene editing in-vivo as a prophylactic for BRCA1 gene mutation-based cancers.

Previously, he was the Product and Engineering Director for Bevel, a startup out of Tufts Dental School making dental hygiene more accessible for children. He also interned at Unqork, where he worked on creating healthtech software applications as well as GTM strategy and client-facing business development. Ze’ev has done research at the Hospital for Special Surgery and Weill Cornell where he co-authored two publications.

Ze’ev is passionate about medical technology and biotechnology, and the intersection of healthcare, product and device design, and entrepreneurship.

Outside of TBR, Ze’ev is the first violin in the Tufts Klezmer Ensemble and plays on the Tufts Rugby team. He also serves on the Associate Board of Row New York and is a volunteer tutor for underprivileged children grades 3-12.

ze_ev.drukker@tufts.edu

https://www.linkedin.com/in/drukker

Awards & Publications

Jerabek SA, Drukker Z, Boyle K. Navigation and Enabling Technologies in Total Hip Arthroplasty. Operative Techniques in Orthopaedic Surgery, 3rd Edition. In review.
Hospital for Special Surgery, NY

Helfet DL, Lorich DG, Drukker Z, Klinger CE. Surgical outcomes of proximal humerus fractures treated with open reduction and internal fixation: Survivorship and complications. In review.
Hospital for Special Surgery & Weill Cornell School of Medicine, NY

Finalist in 2021 Tufts $100k New Ventures Competition
Co-founder/CEO of JEZA Genomics; conducted research and co-wrote proposal for in-vivo gene editing of the BRCA1 gene as a prophylactic for breast, lung, ovarian, pancreatic, and prostate cancers that decreases cancer development by 67-97%.